Coiled TherapeuticsCOTXF 21 EV-to-FCF is -64.77 as of Jun. 24, 2026. GuruFocus rates COTXF with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 328 Biotechnology companies, Coiled Therapeutics ranks worse than 304877.74% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Coiled Therapeutics's Enterprise Value is $56.42 Mil.
Coiled Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.87 Mil. Therefore, Coiled Therapeutics's EV-to-FCF for today is -64.77.
The historical rank and industry rank for Coiled Therapeutics's EV-to-FCF or its related term are showing as below:
COTXF'
s EV-to-FCF Range Over the Past 10 Years
Min: -69.78 Med: 0.02 Max: 0.23
Current: -64.77
During the past 5 years, the highest EV-to-FCF of Coiled Therapeutics was 0.23. The lowest was -69.78. And the median was 0.02.
COTXF's EV-to-FCF is ranked worse than 100% of 328
companies
in the Biotechnology industry
Industry Median: 14.86
vs COTXF: -64.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Coiled Therapeutics's PE Ratio (TTM) for today is calculated as:
Coiled Therapeutics's share price for today is $0.145.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Coiled Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.294.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Coiled Therapeutics EV-to-FCF Related Terms
Coiled Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Coiled Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Coiled Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coiled Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coiled Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Coiled Therapeutics's EV-to-FCF falls into.
Coiled Therapeutics's current Enterprise Value is $56.42 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Coiled Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coiled Therapeutics (COTXF) has a EV-to-FCF of -64.77 as of Jun. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Coiled Therapeutics and its competitors. According to the industry distribution chart, Coiled Therapeutics ranks #999999 out of 328 companies in the Biotechnology industry.
Is Coiled Therapeutics' EV-to-FCF too high?
Coiled Therapeutics' current EV-to-FCF is -64.77. Based on the distribution chart, Coiled Therapeutics ranks #999999 out of 328 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coiled Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Coiled Therapeutics' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Coiled Therapeutics ranks #999999 out of 328 companies for EV-to-FCF. This places Coiled Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 14.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.86, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Coiled Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coiled Therapeutics's current EV-to-FCF is -64.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coiled Therapeutics stock overvalued right now?
Coiled Therapeutics (COTXF) has a current EV-to-FCF of -64.77. The current EV-to-FCF is -64.77. Coiled Therapeutics' overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Coiled Therapeutics (COTXF), the current EV-to-FCF is -64.77 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coiled Therapeutics PLC principal activity of the Company is to develop pre-clinical next generation medicines focused on hard-to-treat cancers. The Group operated in the single business segment of biotechnology.
21GF Score
Get the complete analysis for COTXF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COTXF has been successfully added to your 
